Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Edwin, Derrick, Caroline, Smalls, Danielle, Smith, Hilary, Kremer, Nicole, Weissman, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470466/
https://www.ncbi.nlm.nih.gov/pubmed/32908943
http://dx.doi.org/10.1093/ofid/ofaa285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470466/
https://www.ncbi.nlm.nih.gov/pubmed/32908943
http://dx.doi.org/10.1093/ofid/ofaa285

Ejemplares similares